Pheast Therapeutics, Inc. — Form D/A
Pheast Therapeutics, Inc. of REDWOOD CITY, CA, a company, filed a Form D amendment with the SEC on 2025-04-10. The offering totals $75.3M, of which $75.3M was reported sold. Industry: Other Technology.
Offering
- Filed: 2025-04-10
- Form: D/A
- Accession: 0001943737-25-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $75.3M
- Amount sold: $75.3M
- Investors: 7
- Date of first sale: 2022-01-31
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-463229
Issuer
- Name: Pheast Therapeutics, Inc.
- CIK: 0001943737
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 200 CARDINAL WAY, STE 300, REDWOOD CITY, CA, 94063
- Phone: 650-374-2223
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Irving Weissman | Director | Redwood City, CA |
| Roy Maute | Director | Redwood City, CA |
| Roy Maute | Executive Officer | Redwood City, CA |
| Raphael Rousseau | Executive Officer | Redwood City, CA |
| Steven Gillis | Director | South San Francisco, CA |
| Jacob Vogelstein | Director | Redwood City, CA |
| Amira Barkal | Director | Redwood City, CA |
| Amira Barkal | Executive Officer | Redwood City, CA |
| Thomas Marty | Executive Officer | Redwood City, CA |
Other filings by this issuer (2)
More